RSP - any on biologicals
32264666 2020. Childhood Rheumatic Diseases and COVID-19 Pandemic: An Intriguing Linkage and a New Horizon
32360811 ä. Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts
32256705 2020. Associations between immune-suppressive and stimulating drugs and novel COVID-19?a systematic review of current evidence
32372857 2020. COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: ?what the bleep do we know??
C7160444 ä. Use of systemic immunomodulatory therapies during the coronavirus disease 2019 (COVID-19) pandemic
32330632 ä. Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment
32335173 ä. How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review
32303756 ä. Impact of anti-tnf? antibodies on the risk of Covid-19 and its severity in patients with inflammatory Bowel Diseases
32339915 ä. Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19
32362357 ä. Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum
32314010 ä. Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs
32371550 2020. COVID-19 infection in a patient with multiple sclerosis treated with fingolimod
32315980 2020. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?
32348641 ä. Covid-19 in Immune-Mediated Inflammatory Diseases ? Case Series from New York
32348598 2020. Review article: prevention, diagnosis and management of COVID-19 in the IBD patient
32359205 2020. 2019 Novel Coronavirus Disease (COVID-19) in patients with Inflammatory Bowel Diseases
32243698 ä. Immunosuppression drug?related and clinical manifestation of Coronavirus disease 2019: A therapeutical hypothesis
32312768 2020. Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia
32241792 2020. COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD
32354772 2020. Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept
32332075 2020. Patients with lupus are not protected from COVID-19
32332072 2020. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine
32295789 2020. Role of immunosuppressive therapy in rheumatic diseases concurrent with COVID-19
32327426 2020. SLE patients are not immune to covid-19: importance of sending the right message across
32295787 2020. SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment
